Benzinga · Oct 19, 2026
This Ameriprise Financial Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Analysts downgraded BXP, MDXH, AOS, NMRK and LCII, cutting price targets for BXP, AOS, NMRK and LCII.
NASDAQ · MDXH
Healthcare · Medical - Diagnostics & Research
$0.18
Down-$0.03 (-14.34%)
Updated Oct 23, 2026, 7:15 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MDXH
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 22, 2026
MDXH closed at $0.18 after 21 trading sessions, down 68.38% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 22, 2026 | $0.217 | $0.217 | $0.1755 | $0.184 | 2.97M |
| Oct 21, 2026 | $0.18 | $0.22 | $0.18 | $0.2148 | 2.94M |
| Oct 20, 2026 | $0.185 | $0.1974 | $0.1753 | $0.1944 | 2.65M |
| Oct 19, 2026 | $0.21 | $0.2103 | $0.171 | $0.1832 | 3.93M |
| Oct 16, 2026 | $0.40 | $0.41 | $0.1863 | $0.2066 | 17.31M |
| Oct 15, 2026 | $0.64 | $0.6499 | $0.576 | $0.6036 | 791.5K |
| Oct 14, 2026 | $0.6657 | $0.682 | $0.63 | $0.6317 | 211.67K |
| Oct 13, 2026 | $0.602 | $0.67 | $0.602 | $0.66 | 488.54K |
| Oct 12, 2026 | $0.58 | $0.6119 | $0.58 | $0.6039 | 294.05K |
| Oct 9, 2026 | $0.5754 | $0.5964 | $0.5712 | $0.5897 | 48.14K |
| Oct 8, 2026 | $0.60 | $0.6061 | $0.5752 | $0.5805 | 60.9K |
| Oct 7, 2026 | $0.5939 | $0.6047 | $0.59 | $0.5998 | 333.2K |
| Oct 6, 2026 | $0.61 | $0.6102 | $0.5873 | $0.5999 | 184.52K |
| Oct 5, 2026 | $0.5681 | $0.61 | $0.5603 | $0.5969 | 126.2K |
| Oct 2, 2026 | $0.57 | $0.60 | $0.56 | $0.571 | 79.34K |
| Oct 1, 2026 | $0.60 | $0.60 | $0.5596 | $0.5762 | 117.81K |
| Sep 30, 2026 | $0.5201 | $0.6398 | $0.5201 | $0.5846 | 451.79K |
| Sep 29, 2026 | $0.5316 | $0.5499 | $0.5185 | $0.52 | 311.05K |
| Sep 28, 2026 | $0.56 | $0.5742 | $0.546 | $0.548 | 95.1K |
| Sep 25, 2026 | $0.58 | $0.5999 | $0.5604 | $0.5652 | 236.25K |
| Sep 24, 2026 | $0.6046 | $0.6046 | $0.5628 | $0.582 | 222.72K |
The latest Smart Investors Daily articles mentioning MDXH.
Company
Market Activity
Research & News
MDXH research
Company profile and research snapshot.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 19, 2026 | BTIG | Neutral | — |
| Aug 21, 2026 | BTIG | Buy | — |
| Aug 14, 2026 | Lake Street | Buy | — |
| May 14, 2026 | Lake Street | Buy | — |
| May 14, 2026 | TD Cowen | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 19, 2026
Analysts downgraded BXP, MDXH, AOS, NMRK and LCII, cutting price targets for BXP, AOS, NMRK and LCII.
Benzinga · Oct 19, 2026
BTIG analyst Mark Massaro downgrades MDxHealth (NASDAQ:MDXH) from Buy to Neutral.
Yahoo · Oct 16, 2026
Healthcare stocks were mixed Friday afternoon, with the NYSE Healthcare Index up 0.1% and the State
Benzinga · Oct 16, 2026
U.S. stocks fell Friday, led by Nasdaq’s 1.86% drop; energy rose, communication services sank. Oil topped $100 as CFG beat earnings estimates.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning MDXH.